Drug Profile
Research programme: acute myeloid leukaemia therapy - UCB
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator UCB
- Class Cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Cell replacements; Immunologic cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Acute myeloid leukaemia
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Acute-myeloid-leukaemia in Europe